SERA Logo

Sera Prognostics, Inc. (SERA) 

NASDAQ
Market Cap
$276.05M
Sector
Healthcare
Industry
Medical—Diagnostics & Research
Rank in Sector
711 of 776
Rank in Industry
40 of 42

Largest Insider Buys in Sector

SERA Stock Price History Chart

SERA Stock Performance

About Sera Prognostics, Inc.

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The …

Insider Activity of Sera Prognostics, Inc.

Over the last 12 months, insiders at Sera Prognostics, Inc. have bought $0 and sold $3.38M worth of Sera Prognostics, Inc. stock.

On average, over the past 5 years, insiders at Sera Prognostics, Inc. have bought $9,600 and sold $1.17M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 8,000 shares for transaction amount of $9,600 was made by Jackson Benjamin (General Counsel) on 2022‑06‑14.

List of Insider Buy and Sell Transactions, Sera Prognostics, Inc.

2024-10-07Saledirector
96
0.0003%
$7.15$686+6.79%
2024-09-10SaleChief Executive Officer
25,085
0.0792%
$7.57$189,893+1.15%
2024-09-10SaleChief Financial Officer
5,056
0.016%
$7.57$38,274+1.15%
2024-09-06Saledirector
96
0.0003%
$7.16$687+2.62%
2024-08-07SaleChief Executive Officer
12,327
0.039%
$7.42$91,466-0.54%
2024-08-07SaleChief Financial Officer
6,760
0.0214%
$7.42$50,159-0.54%
2024-08-07SaleChief Data Officer
4,333
0.0137%
$7.42$32,151-0.54%
2024-08-07SaleGeneral Counsel
5,022
0.0159%
$7.42$37,263-0.54%
2024-08-07SaleChief Information Officer
5,022
0.0159%
$7.42$37,263-0.54%
2024-08-07SaleChief Scientific Officer
5,022
0.0159%
$7.42$37,263-0.54%
2024-08-07Saledirector
101
0.0003%
$7.42$749-0.54%
2024-06-10SaleChief Executive Officer
26,867
0.0851%
$8.11$217,891-8.42%
2024-06-10SaleChief Financial Officer
5,415
0.0172%
$8.11$43,916-8.42%
2024-05-15SaleChief Data Officer
10,387
0.0321%
$8.24$85,589-8.83%
2024-05-08SaleChief Executive Officer
11,992
0.039%
$9.59$115,003-17.42%
2024-05-08SaleChief Financial Officer
6,592
0.0215%
$9.59$63,217-17.42%
2024-05-08SaleChief Data Officer
4,205
0.0137%
$9.59$40,326-17.42%
2024-05-08SaleGeneral Counsel
4,902
0.016%
$9.59$47,010-17.42%
2024-05-08SaleChief Information Officer
4,902
0.016%
$9.59$47,010-17.42%
2024-05-08SaleChief Scientific Officer
4,902
0.016%
$9.59$47,010-17.42%

Insider Historical Profitability

51.59%
Jackson BenjaminGeneral Counsel
140255
0.4329%
$8.5215+51.59%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Baker Bros Advisors LP$49.45M16.645.43M0%+$00.36
RA Capital Management, L.P.$18.42M6.22.02MNew+$18.42M0.02
Vivo Capital$15.02M5.051.65M0%+$01.31
The Vanguard Group$8.16M2.74896,163-1.47%-$121,384.90<0.0001
Invesco$5.66M1.9621,834New+$5.66M<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.